Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo

Author(s): Hui Y. Li, Fei Luo, Xiao Y. Li, Xi F. Fu, Jie F. He, Yan Z. Tian, Jun J. Zhu, Xin Y. Chu, Hao L. Zhao*.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 19 , Issue 6 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Multi Drug Resistance (MDR) is the phenomenon that cancers develop resistance to majority of chemotherapy drugs and is a serious obstacle to the treatment for Hepatocellular Carcinoma (HCC). Polo-Like Kinase 1 (PLK1) is a serine/threonine kinase associated with tumor growth and clinical prognosis in HCC and BI2536 is its potent inhibitor with IC50 of 0.83nM.

Aims: To test whether the down-regulation of PLK1 by its inhibitor BI2536 would have beneficial effects on the reversal of MDR in HCC cells.

Methods: The CCK-8 assay was used to determine the viability of HepG2/ADM and SMMC7721/ADM cells and their parental cells treated with BI2536. Then animal model studies were performed. Cell invasion assay and wound healing assay were used to determine the invasion ability and motility. Flow cytometric was used to test the apoptosis induced by BI2536. Western blot and quantitative real-time PCR were performed to test the change of expression of MDR and apoptosis-related gene.

Results: BI2536 down-regulated the expression of PLK1 protein and mRNA specifically. BI2536 can significantly reduce IC50 for ADM and other drugs in ADM-resistant HCC cells. Meanwhile, it inhibited cell viability, proliferation, and invasion, and induced cell cycle arrest and apoptosis in HCC cells with MDR.

Conclusion: Our results suggest that PLK1 inhibitor BI2536 can re-sensitize HCC cancer cell with MDR through induction of apoptosis. Thus, PLK1 inhibitor BI2536 may act as an effective chemotherapeutic drug in the clinical treatment of HCC patients with MDR.

Keywords: Hepatocellular carcinoma, multidrug resistance, polo-like kinase 1, BI2536, apoptosis, chemotherapeutic drug.

[1]
El-Serag, H.B. Hepatocellular carcinoma. N. Engl. J. Med., 2011, 365(12), 1118-1127.
[2]
Arzumanyan, A.; Reis, H.M.; Feitelson, M.A. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer, 2013, 13(2), 123-135.
[3]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[4]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
[5]
Clark, T.; Maximin, S.; Meier, J.; Pokharel, S.; Bhargava, P. Hepatocellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr. Probl. Diagn. Radiol., 2015, 44(6), 479-486.
[6]
Belghiti, J.; Kianmanesh, R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford), 2005, 7(1), 42-49.
[7]
Schwartz, J.D.; Schwartz, M.; Mandeli, J.; Sung, M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: Review of the randomised clinical trials. Lancet Oncol., 2002, 3(10), 593-603.
[8]
Higgins, C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature, 2007, 446(7137), 749-757.
[9]
Vasudevan, S.; Thomas, S.A.; Sivakumar, K.C.; Komalam, R.J.; Sreerekha, K.V.; Rajasekharan, K.N.; Sengupta, S. Diaminothiazoles evade multidrug resistance in cancer cells and xenograft tumour models and develop transient specific resistance: Understanding the basis of broad-spectrum versus specific resistance. Carcinogenesis, 2015, 36(8), 883-893.
[10]
Scheffer, G.L.; Schroeijers, A.B.; Izquierdo, M.A.; Wiemer, E.A.; Scheper, R.J. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr. Opin. Oncol., 2000, 12(6), 550-556.
[11]
Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer, 2018, 18(7), 452-464.
[12]
Chen, Y.L.; Yang, T.Y.; Wu, C.L.; Chen, K.C.; Hsu, S.L.; Hsueh, C.M. Mechanisms underlying Lung Resistance-related Protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells. Chin. J. Physiol., 2016, 59(6), 331-347.
[13]
Folmer, Y.; Schneider, M.; Blum, H.E.; Hafkemeyer, P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther., 2007, 14(11), 875-884.
[14]
Ki, B.G.C.; Lowe, L.; Amedei, A.; Amin, A.R.M.R.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.M.E.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M.F.; Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.Y.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muralidhar, V.; Muqbil, I.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rupasinghe, H.P.V.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Kumara, S.H.M.C.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompson, S.K.; Tran, P.T.; Ungefroren, H.; Heiden, V.M.G.; Venkateswaran, V.; Vinay, D.S.; Vlachostergios, P.J.; Wang, Z.; Wellen, K.E.; Whelan, R.L.; Yang, E.S.; Yang, H.; Yang, X.; Yaswen, P.; Yedjou, C.; Yin, X.; Zhu, J.; Zollo, M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol., 2015, 35(Suppl.), S276-S304.
[15]
de Carcer, G.; Manning, G.; Malumbres, M. From Plk1 to Plk5: Functional evolution of polo-like kinases. Cell Cycle, 2011, 10(14), 2255-2262.
[16]
Ugras, S.; Brill, E.; Jacobsen, A.; Hafner, M.; Socci, N.D.; Decarolis, P.L.; Khanin, R.; O’Connor, R.; Mihailovic, A.; Taylor, B.S.; Sheridan, R.; Gimble, J.M.; Viale, A.; Crago, A.; Antonescu, C.R.; Sander, C.; Tuschl, T.; Singer, S. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res., 2011, 71(17), 5659-5669.
[17]
Liu, X.; Choy, E.; Harmon, D.; Yang, S.; Yang, C.; Mankin, H.; Hornicek, F.J.; Duan, Z. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth In Vitro and In Vivo. Anticancer Drugs, 2011, 22(5), 444-453.
[18]
Stehle, A.; Hugle, M.; Fulda, S. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Cancer Lett., 2015, 365(1), 37-46.
[19]
Weiß, L.M.; Hugle, M.; Romero, S.; Fulda, S. Synergistic induction of apoptosis by a polo-like kinase1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells. Int. J. Cancer, 2015, 138(2), 497-506.
[20]
Pellegrino, R.; Calvisi, D.F.; Ladu, S.; Ehemann, V.; Staniscia, T.; Evert, M.; Dombrowski, F.; Schirmacher, P.; Longerich, T. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology, 2010, 51(3), 857-868.
[21]
Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56(2), 185-229.
[22]
Barrand, M.A.; Heppell-Parton, A.C.; Wright, K.A.; Rabbitts, P.H.; Twentyman, P.R. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J. Natl. Cancer Inst., 1994, 86(2), 110-117.
[23]
Mehta, K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int. J. Cancer, 1994, 58(3), 400-406.
[24]
Luo, F.; Li, H.; Liang, J.; Jia, H.; Li, X.; Xiao, H.; He, X.; He, J.; Tian, Y.; Zhao, H. Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression. Mol. Med. Rep., 2017, 15(4), 2360-2368.
[25]
Steegmaier, M.; Hoffmann, M.; Baum, A.; Lenart, P.; Petronczki, M.; Krssak, M.; Gurtler, U.; Garin-Chesa, P.; Lieb, S.; Quant, J.; Grauert, M.; Adolf, G.R.; Kraut, N.; Peters, J.M.; Rettig, W.J. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol., 2007, 17(4), 316-322.
[26]
Spankuch, B.; Kurunci-Csacsko, E.; Kaufmann, M.; Strebhardt, K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene, 2007, 26(39), 5793-5807.
[27]
Ling, V.; Gerlach, J.; Kartner, N. Multidrug resistance. Breast Cancer Res. Treat., 1984, 4(2), 89-94.
[28]
Choi, J.H.; Lim, H.Y.; Joo, H.J.; Kim, H.S.; Yi, J.W.; Kim, H.C.; Cho, Y.K.; Kim, M.W.; Lee, K.B. Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br. J. Cancer, 2002, 86(10), 1578-1585.
[29]
Petronczki, M.; Lenart, P.; Peters, J.M. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev. Cell, 2008, 14(5), 646-659.
[30]
van Vugt, M.A.; Medema, R.H. Getting in and out of mitosis with Polo-like kinase-1. Oncogene, 2005, 24(17), 2844-2859.
[31]
Yamada, S.; Ohira, M.; Horie, H.; Ando, K.; Takayasu, H.; Suzuki, Y.; Sugano, S.; Hirata, T.; Goto, T.; Matsunaga, T.; Hiyama, E.; Hayashi, Y.; Ando, H.; Suita, S.; Kaneko, M.; Sasaki, F.; Hashizume, K.; Ohnuma, N.; Nakagawara, A. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene, 2004, 23(35), 5901-5911.
[32]
Jackson, J.R.; Patrick, D.R.; Dar, M.M.; Huang, P.S. Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat. Rev. Cancer, 2007, 7(2), 107-117.
[33]
Nappi, T.C.; Salerno, P.; Zitzelsberger, H.; Carlomagno, F.; Salvatore, G.; Santoro, M. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res., 2009, 69(5), 1916-1923.
[34]
Chen, Z.; Chai, Y.; Zhao, T.; Li, P.; Zhao, L.; He, F.; Lang, Y.; Qin, J.; Ju, H. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells. J. Cell. Physiol., 2019, 234(5), 5904-5914.
[35]
Liu, N.; Hu, G.; Wang, H.; Li, Z.; Guo, Z. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells. J. Cell. Mol. Med., 2018, 22(11), 5300-5310.
[36]
Renner, A.G.; Dos Santos, C.; Recher, C.; Bailly, C.; Creancier, L.; Kruczynski, A.; Payrastre, B.; Manenti, S. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood, 2009, 114(3), 659-662.
[37]
Wilson, T.R.; Johnston, P.G.; Longley, D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets, 2009, 9(3), 307-319.
[38]
Hetz, C. BCL-2 protein family. Essential regulators of cell death. Preface. Adv. Exp. Med. Biol., 2010, 687, vii-viii.
[39]
Roos, W.P.; Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol. Med., 2006, 12(9), 440-450.
[40]
Roos, W.P.; Kaina, B. DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett., 2013, 332(2), 237-248.
[41]
Yang, H.H.; Ma, M.H.; Vescio, R.A.; Berenson, J.R. Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J. Clin. Oncol., 2003, 21(22), 4239-4247.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 6
Year: 2019
Page: [740 - 749]
Pages: 10
DOI: 10.2174/1871520619666190301145637
Price: $58

Article Metrics

PDF: 34
HTML: 3
EPUB: 1

Special-new-year-discount